What is AccuraGen?
AccuraGen is at the forefront of genetic technology, uniquely employing rolling-circle amplification for consensus-based concatemer error correction. This innovative approach ensures a high conversion rate while minimizing error proliferation. The company has meticulously optimized its assay to detect a broad spectrum of genetic alterations with sensitivity approaching physical limits and specificity up to 100 times better than benchmarks. This technological prowess positions AccuraGen as a key player in the rapidly evolving field of genomics and molecular diagnostics.
How much funding has AccuraGen raised?
AccuraGen has raised a total of $47M across 3 funding rounds:
Series A
$6.9M
Series B
$40M
Debt
$150K
Series A (2015): $6.9M with participation from Decheng Capital, Dalian Yifang Group Co., WS1 Investments, and Denlux Capital
Series B (2016): $40M led by DT Capital, Stanford University, and Decheng Capital
Debt (2020): $150K supported by PPP
Key Investors in AccuraGen
DT Capital
DT Capital Partners is a private equity firm focused on growth capital for early and expansion stage companies in sectors including Health Care and TMT. They invest in businesses with large market opportunities and strong management teams.
Decheng Capital
Decheng Capital is a global investment firm established in 2012, specializing in providing capital and strategic support to early-stage life science companies and growth stage healthcare companies.
Stanford University
Stanford University is a world-leading research university known for its entrepreneurial character and interdisciplinary approach to problem-solving across various fields, including sciences and engineering.
What's next for AccuraGen?
The substantial enterprise-level backing and recent strategic investment signal a new phase of aggressive scaling and market penetration for AccuraGen. This capital infusion is anticipated to fuel research and development, expand manufacturing capabilities, and bolster commercialization efforts. AccuraGen is poised to leverage this financial momentum to solidify its market leadership and introduce its advanced genetic solutions to a wider audience, potentially disrupting existing diagnostic paradigms and setting new industry standards.
See full AccuraGen company page
